Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PPID | Q08752 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL437664 | 0.87 | ESR1 (0.53) | POLBHSD11B1ALDH1A1MAPTMEN1 | |
| SCHEMBL29983875 | 0.85 | POLB (0.51) | POLBHSD11B1SMN1; SMN2ALDH1A1PPID | |
| SCHEMBL8311559 | 0.84 | OPRM1 (0.49) | POLBHSD11B1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL2636117 | 0.83 | SMN1; SMN2 (0.46) | POLBHSD11B1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL31316615 | 0.83 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL16629075 | 0.81 | SMN1; SMN2 (0.44) | POLBHSD11B1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL9734283 | 0.79 | CCR1 (0.47) | POLBHSD11B1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL5972547 | 0.79 | CYP2C19 (0.61) | POLBHSD11B1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL21447568 | 0.79 | HSD11B1 (0.52) | POLBHSD11B1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL8079696 | 0.79 | HSD11B1 (0.52) | POLBHSD11B1SMN1; SMN2ALDH1A1PPID |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109180613-A | It is a kind of containing bridged ring and and (E)-alpha-methylene-gamma-butyrolactone of ring structure or the synthetic method of furan compound | 华南理工大学 | 2019-01-11 | — | — | CN | disclosed |
| EP-2456309-B1 | Azabicyclo[3.2.1]octyl derivatives for use in the treatment of HIV. | GLAXOSMITHKLINE LLC (US) | 2015-12-23 | — | — | EP | disclosed |
| EP-2456309-B1 | Azabicyclo[3.2.1]octyl derivatives for use in the treatment of HIV. | GLAXOSMITHKLINE LLC (US) | 2015-12-23 | — | — | EP | disclosed |
| US-8592395-B2 | Therapeutic compounds | GLAXOSMITHKLINE LLC (US) | 2013-11-26 | — | — | US | disclosed |
| US-20120295877-A1 | Therapeutic Compounds | GLAXOSMITHKLINE LLC | 2012-11-22 | — | — | US | disclosed |
| US-20120295877-A1 | Therapeutic Compounds | GLAXOSMITHKLINE LLC | 2012-11-22 | — | — | US | disclosed |
| US-20120295877-A1 | Therapeutic Compounds | GLAXOSMITHKLINE LLC | 2012-11-22 | — | — | US | disclosed |
| EP-2456309-A1 | THERAPEUTIC COMPOUNDS | GlaxoSmithKline LLC (US) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011011652-A1 | THERAPEUTIC COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295877-A1 | Therapeutic Compounds | CCR5, CCR1, CXCR3 | POLB 2447/4885HSD11B1 272/4885SMN1; SMN2 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.